VistaGen Therapeutics (VTGN) Q1 2025 earnings summary

Executive summary

• Advancing a novel class of non-systemic, neurocircuitry-focused intranasal drug candidates for social anxiety disorder (SAD), major depressive disorder (MDD), and menopausal hot flashes, all with significant unmet medical needs.

• Lead program is the U.S. registration-directed PALISADE phase III program for fasedienol nasal spray for acute SAD, with PALISADE-3 underway and PALISADE-4 planned for H2 2024.

• Positive phase III results for fasedienol in SAD (PALISADE-2) and positive exploratory phase II results for itruvone (MDD) and PH80 (hot flashes) support further development.

• Itruvone for MDD and PH80 for menopausal hot flashes are advancing, with IND-enabling work and Phase 2 planning ongoing.

• The company operates as a single segment focused on neuroscience drug development, with all revenue derived from sublicense and collaboration agreements.

Financial highlights

• Research and development expenses were $7.6 million for Q1 FY2025, up from $4.2 million year-over-year, mainly due to increased clinical activity and headcount.

• General and administrative expenses rose to $4.6 million from $3.0 million year-over-year, reflecting higher headcount and professional service costs.

• Net loss attributable to common shareholders was $10.7 million for the quarter, compared to $6.9 million in the prior year.

• Cash, cash equivalents, and marketable securities totaled $108.4 million as of June 30, 2024.

• Revenue for the quarter was $0.1 million, down from $0.2 million in the same quarter last year, primarily from sublicense and collaboration agreements.

Outlook and guidance

• Enrollment for PALISADE-3 phase III trial is on track; PALISADE-4 phase III trial initiation expected in the second half of 2024.

• Both PALISADE-3 and PALISADE-4, along with an exploratory phase II-A repeat dose study, are expected to read out in 2025.

• Phase IIb protocol for itruvone in MDD to be submitted to the FDA before year-end, with trial initiation expected after regulatory feedback.

• Ongoing non-clinical work for PH80 to enable U.S. phase II development for menopausal hot flashes.

• Current cash resources are expected to fund operations for more than 12 months from the financial statement issuance date.